Kornimate/medical-research-clean huggingface dataset:
efficacy and safety of mesotherapy with minoxidil 0.5%/2ml for androgenetic alopecia in female patients

Conditions: Female Pattern Alopecia

Summary: this study aims to investigate the effectiveness and safety of mesotherapy for the treatment of female pattern alopecia. * sixty female subjects between 18 and 65 years diagnosed with female pattern hair loss will undergo mesotherapy sessions weekly for ten weeks. * one group will receive 0.5%/2ml minoxidil application and a control group will receive application of placebo (saline 0.9%). * biopsy of the scalp, trichogram and trichoscopy (fotofinder) will be performed before and 08 weeks after treatment as a method objective evaluation of the response

this is a trial that aims to analyze the efficacy and safety of mesotherapy with minoxidil 0,5% versus placebo for androgenetic alopecia in female patients. the patients and the investigators who analyzes complementary exams are blind. * clinical criteria, photo, 4mm biopsia, trichogram and trichoscopy are perfomed before patients are randomized into two arms : 1. group 1 (placebo): 30 patients who will have intradermal injections in the scalp of saline 0.9% 2. group 2 (active drug): 30 patients who will receive intradermal injections in the scalp with minoxidil 0.5%/2ml eight weeks after the last session patients will be recruited for repeat the exams and perform a self-assessment of both the effect on hair growth and the effect on hair loss.

Eligibility criteria:
inclusion criteria: * women from 18 to 65 years old * androgenetic alopecia (female pattern hair loss) exclusion criteria: * patients with alopecia areata or cicatricial alopecia * pregnancy and breastfeeding * have undergone any specific treatment in the last 06 months * use of drugs with anti-androgenic properties * patients with signs or symptoms of hyper-androgynism

Keywords: androgenetic alopecia mesotherapy minoxidil trichogram
venous thromboembolism in advanced lung cancer

Conditions: Lung Neoplasms; Venous Thromboembolism

Summary: this is a prospective observatory clinical study, aiming to establish and validate venous thromboembolism risk model in chinese advanced non-small cell lung cancer.

vte has high incidence in lung cancer and increases the mortality. appropriate preventive measures contribute to 50% increase of incidence. the investigators are to investigate the vte in advanced non-small cell lung cancer and delineate the risk factors to establish a vte risk model system helping clinicians to differentiate vte high risk population and apply early prevention in order to reduce the incidence of vte.

Eligibility criteria:
inclusion criteria: * age ≥ 18 years at the time of screening. * eastern cooperative oncology group performance status of ≤ 2. * written informed consent obtained from the patient. * histologically and cytologically documented stage 3b-4 lung cancer (according to version 8 of the international association for the study of lung cancer staging system). * patients with stage 1 to 3, who undergo radical therapy with disease free survival (dfs) \>12 months. * willingness and ability to comply with scheduled visits and other study procedures. exclusion criteria: * history of another primary malignancy except for malignancy treated with curative intent with known active disease ≥ 5 years before date of the informed consent. * without signed informed consent. * unwillingness or inability to comply with scheduled visits or other study procedures. * previously diagnosed with vte before signing informed consent.

Keywords: lung cancer venous thromboembolism
mobile intervention supervised exercise therapy study 1

Conditions: Peripheral Artery Disease; Claudication, Intermittent

Summary: this is a randomized controlled trial evaluating the impact of the mobile phone delivered svs set program on utilization, functional capacity, symptoms and quality of life.

this is a national randomized controlled study with approximately 10-15 sites enrolling patients with rutherford ii peripheral artery disease (pad) in total. patients will be randomized between the svs set program and "usual care" for each site. the primary outcome will be to study the site-specific effect on utilization of exercise therapy. secondary outcomes will be the effect on the 6-minute-walk test, passive activity and quality of life.

Eligibility criteria:
inclusion criteria: * 18 years of age * rutherford class i-ii pad (claudication) * ambulatory * exercise therapy naive (\>18 mo) * primary owner of an android or ios device * willingness to participate (text, call, fill out surveys) via a mobile phone exclusion criteria: * symptomatic coronary artery disease * oxygen dependent copd * significant osteoarthritis limiting ambulation
a study to investigate the effect of delayed release pancrelipase on maldigestion in patients with exocrine pancreatic insufficiency due to chronic pancreatitis and pancreatectomy

Conditions: Chronic Pancreatitis; Pancreatectomy; Pancreatic Exocrine Insufficiency

Summary: this study assessed the effect of pancrelipase delayed release capsules on fat and nitrogen absorption in subjects with pei due to chronic pancreatitis and pancreatectomy. there was a run-in with a 5-day of single-blind placebo treatment, followed by a 7-day double-blind period and a 6-month open-label follow-up.


Eligibility criteria:
inclusion criteria: pancreatic exocrine insufficiency has to be proven (in medical history) by the following criteria: * direct or indirect pancreatic function test (except stool fat excretion) or clinical signs of severe steatorrhoea that resolved upon administration of pancreatic supplementation. * total stool fat \> 40 g over 4 days (using van de kamer method) * proven chronic pancreatitis * females of child-bearing potential must agree to continue using a medically acceptable method of birth control exclusion criteria: * ileus or acute abdomen * any type of malignancy involving the digestive tract in the last 5 years * presence of pseudo-pancreatic cyst ≥ 4 * continued excessive intake of alcohol or drug abuse * known infection with hiv

Keywords: chronic pancreatitis pancreatectomy pancreatic exocrine insufficiency
use of chitosan powder in loop electrosurgical excision procedure

Conditions: Vaginal Bleeding; Loop Electrosurgical Excision

Summary: early treatment of cervical intraepithelial neoplasia (cin) ii-iii gives rise to a decrease in the incidence of invasive cervical cancer. though there is no obvious consensus from randomized studies as to the optimal management of cin ii-iii, loop electrosurgical excision procedure (leep) is the most extensively used method because of its technical ease, inexpensive, steep learning curve, and low rate of complications. in spite of these benefits, current literature suggests that some patients experience some complications such as postoperative vaginal bleeding, abnormal vaginal discharge, abdominal pain, and infection. these adversely affect the recovery period, increase patient anxiety, readmission to the hospital for further treatment and encumber patients' daily life. postoperative vaginal bleeding (pvb) is one of the most common and unpleasant of these complications. its incidence has been reported to vary between 2% to 78%. many different types of treatments have been applied to avert or diminish pvc such as the use of vasopressin, tranexamic acid, monsel's solution, and local hemostats (e.g., tachosil or tisseel), but these attempts have failed to show precise benefits over routine clinical approaches. chitosan is a biodegradable, natural polyaminosaccharide with a nontoxic, non-allergenic, positively-charged polysaccharide derived from the deacetylation of chitin. due to its molecular characteristics, chitosan has been used for improved hemostasis. furthermore, chitosan has an antimicrobial and wound-healing effect. the current literature concerning the influence of using chitosan after the leep is limited to only one trial. the authors of that study reported that using chitosan after the leep can reduce vaginal bleeding and enhancing wound healing. however, that study has some limitations. therefore, investigators designed this randomized trial to assess the effect of local chitosan implementation on postoperative vaginal bleeding and wound healing in leep


Eligibility criteria:
inclusion criteria: * women were aged \> 21 years old * women were not pregnant * women who were undergoing leep. exclusion criteria: * women with pelvic infection * women with abnormal vaginal bleeding * women with coagulopathy * women with chronic pain syndromes * women with psychiatric disorders * women with the previous hysterectomy with removal of the cervix, * women with a history of cervical cancer * women who could not complete follow-up calls
the prevention of osteoporosis in premenopausal and newly postmenopausal (up to 8 years) women with breast cancer following chemotherapy (rebbeca study)

Conditions: Osteoporosis

Summary: the purpose of this study is to evaluate the effectiveness of once weekly risedronate in the prevention and treatment of bone loss in premenopausal and newly menopausal women with breast cancer who have received chemotherapy. the hypothesis is that bisphosphonate therapy will prevent bone loss at clinically relevant sites, such as the hip and spine. the investigators also hypothesize that there will be a correlation between biochemical markers of bone turnover and changes in bone mineral density.

breast cancer is a significant public health problem accounting for approximately 30% of new cancers diagnosed annually. much advancement has been made in the treatment of these cancers which has significantly decreased the mortality rates. treatment, including adjuvant chemotherapy and hormonal therapy, prolongs disease free survival and overall survival of patients with breast cancer. the cytotoxic drugs, however, can cause premature ovarian failure and subsequent menopause. this risk has been reported to range from 53% to 89%. temporary or permanent chemotherapy induced ovarian failure is important because of potential bone loss associated with the estrogen loss. initiating a potent antiresorptive agent, risedronate, should prevent or improve bone mass in these women. comparison: the investigators will compare bone mass/markers of study subjects receiving risedronate with study subjects receiving placebo. all subjects will be provided calcium and vitamin d supplementation as needed.

Eligibility criteria:
inclusion criteria: * pre- and newly postmenopausal (up to 8 years) women ages 18 and older * breast cancer treated with chemotherapeutic agents, with or without tamoxifen/aromatase inhibitors * negative pregnancy test exclusion criteria: * stage 4 breast cancer * any illness or medications known to affect bone metabolism * history of osteoporosis or history of vertebral or hip fractures * kidney stones in the past 5 years * active peptic ulcer disease
neoadyuvant high-dose of ifosfamide and concurrent radiotherapy in soft tissue sarcoma

Conditions: Soft Tissue Sarcoma

Summary: to study the activity and toxicity of a neoadjuvant regimen including high-dose ifosfamide in combination with radiotherapy, and subsequent surgery, in high-risk soft tissue sarcomas.

this is a phase ii multicenter study designed in two phases. a total of 32 patients will be included in 10 hospitals belonging to the spanish group for research in sarcomas (geis). selection criteria are: patients with localized soft tissue sarcoma from the extremities or trunk with high-risk features (\>5 cm and grade 2-3), or recurrences after prior inadequate surgery. the treatment schedule will be: initial biopsy, 3 cycles of high-dose ifosfamide, 12 gr/m2 in 5 days, concurrent with radiotherapy 50 gy, and subsequent wide surgery. to assess the predictive factors of response to the combination therapy, dna and rna extraction will be performed on the pretreatment biopsies. dna will be used to hybridize affymetrix genechip® human mapping 500k array, which allows for the study of 500000 snps throughout the genome. the expression of 39000 rna transcripts will be evaluated employing the affymetrix genechip human genome hg-u133 plus 2.0, and validated by real-time rt-pcr.

Eligibility criteria:
inclusion criteria: 1. patients with advanced soft tissue sarcoma histological proven, potentially resected, located in extremities and trunk for one of the following histological subtypes: leiomyosarcoma, undifferentiated pleomorphic sarcoma, synovial sarcoma, liposarcoma and malignant tumour of peripheral nerve sheath. 2. primary tumour: 1. size ³ 5 cm of diameter 2. histological grade 2-3 3. deep location 3. no distant metastases 4. patients must have not been previously treated with chemotherapy or radiotherapy on the tumour area. 5. however patients are eligible with local relapse after previous surgery. 6. patients must be £18 and ³ 65 years old. 7. patients must have ecog performance status 0 to 1 8. patients must have measurable disease by recist criteria. 9. absolute neutrophil count ³1,500/mm3, platelet count ³ 100,060 ml/min, creatinine, total bilirubin, alt and ast £ 1.5 times the upper limit of normal 10. signed informed consent prior to any study specific procedures exclusion criteria: 1. patients with cerebral metastasis 2. pregnant or breast feeding patients. 3. active infection or other concomitant severe illness. 4. severe psychiatric illness which would not make possible the obtention of the informed consent 5. concurrent treatment with other experimental drugs within 30 days prior to study entry. 6. history of previous treated or diagnosed cancer in the past 5 years, excepting basocellular cell skin cancer, cervix cancer in situ or superficial bladder carcinoma.

Keywords: sarcoma ifosfamide
a rollover study of ixabepilone (bms-247550) in patients with metastatic breast cancer previously treated with an anthracycline

Conditions: Metastatic Breast Cancer

Summary: to provide extended access to ixabepilone therapy to subjects with metastatic breast cancer who have completed the previous phase ii study (ca163-107)


Eligibility criteria:
inclusion criteria: * women aged 20 years or older * patients with metastatic breast cancer whose primary lesion was definitely diagnosed to be breast by histological or cellular examination exclusion criteria: * patients with an eastern cooperative oncology group (ecog) performance status (ps) of ≥2
improving cardiac secondary prevention

Conditions: Myocardial Infarction; Secondary Prevention

Summary: the purpose of this study is to determine whether providing individuals with personalized information on cellular aging, including telomere length, will stimulate them to adhere to cardiac prevention strategies and improve exercise capacity.

individuals who have sustained a heart attack are at considerable risk for future cardiac events. a cardiac rehabilitation and exercise program can reduce this risk but it remains a challenge to adopt optimum lifestyle changes. we will determine whether providing individuals with information on leukocyte telomere length, will motivate them to improve their exercise performance. we will test whether professionally conveying this information will stimulate an individual to adhere to proven cardiac prevention strategies, looking at the extent to which one's exercise capacity improves over time.

Eligibility criteria:
inclusion criteria: 1. individuals who have sustained a myocardial infarction and entered the cardiac rehabilitation program exclusion criteria: 1. individuals with genetic mutations that affect telomere length 2. individuals who may not have the mental capacity to understanding the ramifications of risk biomarkers
communication memory of cancer diagnosis within the pediatric triangle

Conditions: Memory

Summary: present project aims to investigate memories related to a cancer communication diagnosis in pediatric oncology. it evaluates possible common elements and specificity between family and healthcare staff.

lots of scientific evidences have shown that autobiographical episodes' narrative has a beneficial effect on the elaboration of memories. indeed, narrating is a way to order thoughts and moods, which are connected to particular episodes of one's life, in order to rework and relive them. since the diagnosis, a relationship and an open and sincere dialogue between the various parts of the pediatric triangle can promote a process of adaptation to the experience of illness and an integrated biopsychosocial healing. the first aim of this study is to explore and analyze autobiographical memories of pediatric patients, parents and healthcare staff. also, it aims to investigate possible common and discordant element between deposition. phases of the present study: 1. sample recruitment and informed consent collection. 2. diagnosis communication audio recording. 3. communication of the autobiographical memory of the diagnosis audio recording of patients, parents, oncologist, nurse and psychologists involved, the day after the communication. 4. questionnaire apam administration for adult participants. 5. audio transcription and data coded. data will be registered and operated by means of statistical software as spss (ibm) and t-lab (lancia, 2004). 6. statistical processing: anova and t of student tests will be implemented in order to compare collected questionnaires. narrative analysis will be implemented by means of textual analysis software.

Eligibility criteria:
inclusion criteria for pediatric patients: * age from 12 to 17 with cancer diagnosis only taken by meyer children's hospital prior consent. * italian speaking exclusion criteria for pediatric patients: * under 12 years old and above 17; * followed by other hospital; * cognitive disability inclusion criteria for parents: - italian speaking and signature informed consent. exclusion criteria for parents: - cognitive disability

Keywords: memory pediatric cancer oncology communication diagnosis
a follow up study of intramuscular olanzapine depot in patients with schizophrenia or schizoaffective disorder

Conditions: Schizophrenia; Schizoaffective Disorders

Summary: the purpose of this study is to assess the long-term efficacy of olanzapine pamoate (op) depot in patients diagnosed with schizophrenia or schizoaffective disorder.

since its introduction in the united states and europe in the mid-1990s, olanzapine has been distinguished from other antipsychotic medications (including other "atypical" compounds) by its superior efficacy and safety profiles (beasley et al. 1996a, 1996b; tollefson et al. 1997). only older "typical" antipsychotics have been available in long-acting (depot) formulations. they are most frequently prescribed to enhance compliance and, to a lesser degree, for convenience, as the need for daily oral dosing is eliminated. the popularity of depot formulations has diminished since the introduction of highly effective oral atypical antipsychotics with vastly reduced side effects. however, long-acting injections remain an important treatment option for many patients with psychotic disorders, and the need to provide a safer, more effective depot formulation to this population is compelling. accordingly, an "atypical" depot of olanzapine, which can be administered every 2 to 4 weeks, has been developed to enhance convenience and compliance with antipsychotic therapy. the depot formulation of olanzapine (ly170053) to be evaluated in this study is olanzapine pamoate monohydrate (opm) (the salt of pamoic acid and olanzapine), suitable for deep intramuscular injection. olanzapine pamoate (op) depot (formerly referred to as im olanzapine depot in previous versions of protocol) consists of opm powder, which is suspended in an aqueous vehicle immediately prior to use. several pamoate salts of other registered drug products are currently approved for chronic oral administration in the united states (for example, hydroxyzine pamoate and imipramine pamoate). another pamoate salt depot for intramuscular injection has also been approved in the us (trelstartm la, triptorelin pamoate for injectable suspension) for the treatment of prostate cancer. as of march 2002, the pamoate formulation of op depot has been tested in 12 healthy subjects and approximately 250 patients with schizophrenia in 2 clinical pharmacology studies, f1d-ew-loaz and f1d-ew-lobe, respectively, and one receptor occupancy (positron emission tomography) study, f1d-ew-hgjw. dosages included single doses up to 450mg and multiple doses up to 405mg every 4weeks. this open-label study will assess long-term efficacy 280 mg to 405mg of op depot administered on a 3-week interval in patients with schizophrenia or schizoaffective disorder

Eligibility criteria:
inclusion criteria: * two patients that have been stabilized on op depot will be enrolled to the follow-up study
the impact of nurses' emotional labor on job satisfaction and burnout

Conditions: Satisfaction

Summary: emotional labor is one of the bases that organizations earn profits. nursing care needs high emotional labor to offer health care to patients. among health carers that emphasize a lot on emotional labor, nurses are especially required to include emotional labor as very important parts of their jobs.

this study intends to investigate the association among emotional labor, job satisfaction, and burnout. furthermore, the moderating effect of job stress , job involvement and emotional intelligence will be studied. the study population includes all nurses (n=18,446) of taiwan's medical centers. of which, 20% of randomly selected six medical centers will be delivered a questionnaire in order to further analyze the association of study variables. the level of emotional labor, burnout, job satisfaction, job stress, job involvement and emotional intelligence of the study samples collected from questionnaires will be analyzed by using descriptive statistics, variance analyses, and sem techniques in order to understand more the associations among study variables. results of this study are expected to work as references to improve job satisfaction and decrease the level of burnout of nurses.

Eligibility criteria:
inclusion criteria: * licensed nurses in the hospitals exclusion criteria: * part-time nurses * nurses who work under a year in the hospitals

Keywords: emotional labor burnout job satisfaction emotional intelligence job stress job involvement
impact of an automated telephone intervention on glycosylated hemoglobin (hba1c) in type 2 diabetes

Conditions: Type 2 Diabetes

Summary: aim 1. determine the impact of a daily, automated telephone intervention on hba1c levels compared to standard care in older patients with type 2 diabetes. aim 2. determine the impact of the automated telephone intervention compared to standard care on adherence to prescribed smbg frequency in older patients with type 2 diabetes. aim 3. determine the impact of the automated telephone intervention compared to standard care on self-reported diabetic control problems in older patients with type 2 diabetes. aim 4. determine the impact of the automated telephone intervention compared to standard care on self-reported attitudes and health beliefs concerning diabetes in older patients with type 2 diabetes


Eligibility criteria:
inclusion criteria: * age greater or equal to 55 * type 2 diabetes * english speaking * ability to use glucose meter exclusion criteria: * unable to give informed consent * unwilling to allow smbg levels to be shard with primary care physician

Keywords: type 2 diabetes telephone intervention automated